New antithrombotic drugs: Potential for use in oncology

Journal of Clinical Oncology

Volumn 27, Issue 29, 2009, Pages 4912-4918

  Levine, Mark N ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; XIMELAGATRAN; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG SCREENING; HIGH RISK POPULATION; HISTORY OF MEDICINE; HUMAN; LEG THROMBOSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; HOSPITALIZATION; MALE; MORTALITY; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MORPHOLINES; NEOPLASMS; PROGNOSIS; PYRAZOLES; PYRIDONES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 70350726563     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.7346     Document Type: Review

References (42)

1. Lee AY, Levine MN, Baker RI, et al: A randomized trial of long-term dalteparin low molecular weight heparin versus oral anticoagulant therapy in cancer patients with venous thromboembolism. N Engl J Med 349:146-153, 2003
2. Weitz J, Hirsh J, Samama M: New Antithrombotic Drugs. Chest 133:234S-256S, 2008 (suppl)
3. McLean J: The thromboplastic action of cephalin. Am J Physiol 41:250-257, 1916
4. Howell WH: Heparin, an anticoagulant. Am J Physiol 63:434-435, 1922
5. Howell WH, Holt E: The purification of heparin and its presence in the blood.AmJ Physiol 71:553-562, 1925
6. Howell WH, Holt E: The purification of heparin and its chemical and physiological reactions. Bull Johns Hopkins Hosp 42:199-206, 1928
7. Best CH: Heparin and thrombosis: Harvey Lecture, November 28, 1940. Bull N Y Acad Med 17(10):796-817, 1941
8. Wardrop D, Keeling D: The story of the discovery of heparin and warfarin. Br J Haematol 141:757-763, 2008
9. Charles AF, Scott DA: Studies on heparin: I. The preparation of heparin. The Journal of Biological Chemistry 102:425-429, 1933
10. Charles AF, Scott DA: Studies on heparin: IV. Observations on the chemistry of heparin. Biochem J 30:1927-1933, 1936
11. Mueller RL, Scheidt S: History of Drugs for Thrombotic Disease. Discovery, Development, and Directions for the Future. Circulation 89:432-449, 1993
12. Schofield FW: Hemorrhagic sweet clover disease in cattle. Can Vet Rec 3:74-75, 1922
13. Schofield FW: Damaged sweet clover: The cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg. J Am Vet Med Assoc 64:553-572, 1924
14. Link KP: The anticoagulant from spoiled sweet clover hay. Harvey Lectures Series 34:162-207, 1943
15. Link KP: The discovery of dicumarol and its sequels. Circulation 19:97-107, 1959
16. Barritt DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1:1309-1312, 1960
17. Hirsh J, Bauer KA, Donati MB, et al: Parenteral anticoagulants. Chest 133:141S-159S, 2008 (suppl)
18. Turpie AG, Levine MN, Hirsh J, et al: A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315:925-929, 1986
19. Heit JA: The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery. Arch Int Med 162:1806-1808, 2002
20. Lassen MR, Bauer KA, Eriksson BI, et al: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison. Lancet 359:1715-1720, 2002
21. Turpie AG, Bauer KA, Eriksson BI, et al: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial. Lancet 359:1721-1726, 2002
22. Bauer KA, Eriksson BI, Lassen MR, et al: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345:1305-1310, 2001
23. Eriksson BI, Bauer KA, Lassen MR, et al: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery. N Engl J Med 345:1298-1304, 2001
24. Turpie AGG, Bauer KA, Eriksson BI, et al: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A Meta-analysis of four randomized double-blind studies. Arch Intern Med 162:1833-1840, 2002
25. Agnelli G, Bergqvist D, Cohen AT, et al: Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92:1212-1220, 2005
26. Büller HR, Davidson BL, Decousus H, et al: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702, 2003
27. Büller HR, Davidson BL, Decousus H, et al: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 140:867-873, 2004
28. Agnelli G, Gallus A, Goldhaber SZ, et al: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deepvein thrombosis) study. Circulation 116:180-187, 2007
29. Buller HR, Lensing AW, Prins M, et al: A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT Dose-Ranging Study. Blood 112:2242-2247, 2008
30. Buller H, Deitchman D, Prins M, et al: Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis: The Botticelli DVT dose-ranging study. J Thromb Haemost 6:1313-1318, 2008
31. Eriksson BI, Borris LC, Friedman RJ, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765-2775, 2008
32. Kakkar AK, Brenner B, Dahl OE, et al: Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet 372:31-39, 2008
33. Lassen MR, Ageno W, Borris LC, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358: 2776-2786, 2008
34. Turpie G, Lassen, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial. Lancet 373(9676):1673-1680, 2009
35. Lassen MR, Raskob GE, Gallus A, et al: Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594-604, 2009
36. Lassen MR, Davidson BL, Gallus A, et al: The efficacy and safety of apixaban, an oral, direct factor of Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368-2375, 2007
37. Eriksson BI, Dahl OE, Rosencher N, et al: Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost 5:2178-2185, 2007
38. Eriksson BI, Dahl OE, Rosencher N, et al: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomized, double-blind, non-inferiority trial. Lancet 370:949-956, 2007
39. Friedman RJ, Caprini JA, Comp PC, et al: Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty. J Thromb Haemost 5:OC051, 2007 (suppl 2)
40. Bergqvist D, Agnelli G, Cohen AT, et al: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975-980, 2002
41. Levine MN, Deitchman D, Julian J, et al: A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol 27:15S, 2009 (suppl; abstr e20514)
42. Lohrmann J, Becker RC: New Anticoagulants: The path from discovery to clinical practice. N Engl J Med 358:2827-2829, 2008